Department of Medicine, Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Science Center, New Orleans, LA, United States of America.
Louisiana Clinical and Translational Science Center (LACaTS) Roadmap Scholars Program, New Orleans, LA, United States of America.
PLoS One. 2017 Oct 18;12(10):e0186615. doi: 10.1371/journal.pone.0186615. eCollection 2017.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. Histone deacetylase 6 (HDAC6) alters function and fate of various proteins via deacetylation of lysine residues, and is implicated in TGF-β1-induced EMT (epithelial-mesenchymal transition). However, the role of HDAC6 in pulmonary fibrosis is unknown.
HDAC6 expression in IPF and control lungs was assessed by quantitative real-time PCR (qRT-PCR) and immunoblots. Lung fibroblasts were treated with TGF-β1 ± HDAC6 inhibitors (Tubacin, Tubastatin, ACY1215, or MC1568), and fibrotic markers such as type I collagen were assessed using qRT-PCR and immunoblots. Mice were treated with bleomycin (oropharyngeal aspiration; single dose) ± Tubastatin (intraperitoneally injection; daily for 21 days), and lung collagen expression was gauged using immunoblots and trichrome staining. In a separate experiment, HDAC6 wild-type (WT) and knockout (KO) mice were administered bleomycin, and lungs were evaluated in the same manner.
HDAC6 expression was deregulated in IPF lungs. Among the HDAC6 inhibitors tested, only Tubastatin significantly repressed TGF-β1-induced expression of type-1 collagen in lung fibroblasts, and this finding was coupled with decreased Akt phosphorylation and increased Akt-PHLPP (PH domain and Leucine rich repeat Protein Phosphatase) association. Tubastatin repressed TGF-β1-induced S6K phosphorylation, HIF-1α expression, and VEGF expression. Tubastatin also repressed TGF-β1-induced inhibition of LC3B-II (a marker of autophagosome formation). In bleomycin-treated mouse lungs, HDAC6 expression was increased, and Tubastatin repressed type-1 collagen expression. However, in HDAC6 KO mice, bleomycin-induced type-1 collagen expression was not repressed compared to WT mice. Knockdown of HDAC6, as well as HDAC10, another potential Tubastatin target, did not inhibit TGF-β1-induced collagen expression in lung fibroblasts.
HDAC6 expression is altered during lung fibrogenesis. Tubastatin represses TGF-β1-induced collagen expression, by diminishing Akt phosphorylation and regulating downstream targets such as HIF-1α-VEGF axis and autophagy. Tubastatin-treated WT mice are protected against bleomycin-induced fibrosis, but HDAC6 KO mice are not. Our data suggest that Tubastatin ameliorates pulmonary fibrosis, by targeting the TGFβ-PI3K-Akt pathway, likely via an HDAC6-independent mechanism.
特发性肺纤维化(IPF)是一种慢性、进行性和致命性疾病。组蛋白去乙酰化酶 6(HDAC6)通过去乙酰化赖氨酸残基改变各种蛋白质的功能和命运,并与 TGF-β1 诱导的 EMT(上皮-间充质转化)有关。然而,HDAC6 在肺纤维化中的作用尚不清楚。
通过定量实时 PCR(qRT-PCR)和免疫印迹评估 IPF 和对照肺中的 HDAC6 表达。用 TGF-β1±HDAC6 抑制剂(Tubacin、Tubastatin、ACY1215 或 MC1568)处理肺成纤维细胞,并通过 qRT-PCR 和免疫印迹评估 I 型胶原等纤维化标志物。用博来霉素(口咽吸入;单次剂量)±Tubastatin(腹腔注射;每天 21 天)处理小鼠,并通过免疫印迹和三色染色评估肺胶原表达。在另一个实验中,用博来霉素处理 HDAC6 野生型(WT)和敲除(KO)小鼠,并以相同的方式评估肺部。
HDAC6 在 IPF 肺中表达失调。在所测试的 HDAC6 抑制剂中,只有 Tubastatin 能显著抑制 TGF-β1 诱导的肺成纤维细胞 I 型胶原的表达,这一发现与 Akt 磷酸化减少和 Akt-PHLPP(PH 结构域和富含亮氨酸重复蛋白磷酸酶)结合增加有关。Tubastatin 抑制 TGF-β1 诱导的 S6K 磷酸化、HIF-1α 表达和 VEGF 表达。Tubastatin 还抑制 TGF-β1 诱导的 LC3B-II(自噬体形成的标志物)抑制。在博来霉素处理的小鼠肺中,HDAC6 表达增加,Tubastatin 抑制 I 型胶原表达。然而,在 HDAC6 KO 小鼠中,与 WT 小鼠相比,博来霉素诱导的 I 型胶原表达没有受到抑制。敲低 HDAC6 以及另一种潜在的 Tubastatin 靶点 HDAC10,并未抑制肺成纤维细胞中 TGF-β1 诱导的胶原表达。
HDAC6 在肺纤维化过程中表达发生改变。Tubastatin 通过减少 Akt 磷酸化并调节下游靶标如 HIF-1α-VEGF 轴和自噬,抑制 TGF-β1 诱导的胶原表达。用 Tubastatin 处理的 WT 小鼠对博来霉素诱导的纤维化有保护作用,但 HDAC6 KO 小鼠没有。我们的数据表明,Tubastatin 通过靶向 TGFβ-PI3K-Akt 通路,可能通过一种 HDAC6 非依赖性机制,改善肺纤维化。